Besoin d’Aide pour Analyser et Interpréter Vos Données ?
AltraBio est une société de recherche sous contrat spécialisée dans l’analyse de données biologiques et médicales. Nous utilisons des méthodes statistiques et l’intelligence artificielle pour extraire des informations précieuses.
Confiance Mondiale : AltraBio est un partenaire de recherche et développement reconnu mondialement. Nous collaborons avec des entreprises leaders et des hôpitaux universitaires dans les secteurs pharmaceutiques, des dispositifs médicaux, des diagnostics, et de la dermo-cosmétique.
Comment Collaborer ?
Partenariat
Développement d’outils computationnels pour l’analyse de données au sein de consortiums régionaux, nationaux et internationaux.
Exemples de Projets Actuels et Terminés :
-
SCAnIO : Plateforme Économique pour l’Analyse de Cellules Uniques en Immuno-Oncologie.
-
MEMOIRE : Modélisation Multi-Échelle de la Réponse Immune des Lymphocytes T CD8.
-
PEST-BIN : Stratégies Innovantes contre les Infections Bactériennes.
-
SIGNATURE : Étude des Cellules Uniques dans les Maladies Auto-Immunes Inflammatoires
Sous-traitance
Analyse de données pour des entreprises et des hôpitaux universitaires.
-
Des centaines de projets réalisés.
-
Clients réguliers : Parmi les 10 premières entreprises pharmaceutiques et leaders en cosmétique.
Financement





Nouvelles
mai 2025
Identification de Nouveaux Déterminants de la Pathogénicité Bactérienne par Analyse Phylogénétique
🚀 Dans le cadre du projet PEST-BIN, nous sommes [...]
mars 2025
Vaccin Grippe : Amélioration de l’Immunité Innée chez les Personnes Âgées
Vaccin Grippe : Amélioration de l'Immunité Innée chez les [...]
janvier 2025
Skin Science Days
🚀 AltraBio sera présent aux Skin Science Days 2025, [...]
décembre 2024
27e congrès de l’Association Française de Cytométrie
🚀 AltraBio est ravi d'annoncer sa participation au Congrès [...]
Dernières Publications
2025
Ribeiro, Sara; Alves, Karine; Nourikyan, Julien; Lavergne, Jean-Pierre; de Bernard, Simon; Buffat, Laurent
Identifying potential novel widespread determinants of bacterial pathogenicity using phylogenetic-based orthology analysis Article de journal
Dans: Front. Microbiol., vol. 16, 2025, ISSN: 1664-302X.
@article{Ribeiro2025,
title = {Identifying potential novel widespread determinants of bacterial pathogenicity using phylogenetic-based orthology analysis},
author = {Sara Ribeiro and Karine Alves and Julien Nourikyan and Jean-Pierre Lavergne and Simon de Bernard and Laurent Buffat},
doi = {10.3389/fmicb.2025.1494490},
issn = {1664-302X},
year = {2025},
date = {2025-05-01},
urldate = {2025-05-01},
journal = {Front. Microbiol.},
volume = {16},
publisher = {Frontiers Media SA},
abstract = {<jats:sec><jats:title>Introduction</jats:title><jats:p>The global rise in antibiotic resistance and emergence of new bacterial pathogens pose a significant threat to public health. Novel approaches to uncover potential novel diagnostic and therapeutic targets for these pathogens are needed.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>In this study, we conducted a large-scale, phylogenetic-based orthology analysis (OA) to compare the proteomes of pathogenic to humans (HP) and non-pathogenic to humans (NHP) bacterial strains across 734 strains from 514 species and 91 families.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Using a dedicated workflow, we identified 4,383 hierarchical orthologous groups (HOGs) significantly associated with the HP label, many of which are linked to critical factors such as stress tolerance, metabolic versatility, and antibiotic resistance. Both known virulence factors (VFs) and potential novel widespread pathogenicity determinants were uncovered, supported by both statistical testing and complementary protein domain analysis.</jats:p></jats:sec><jats:sec><jats:title>Discussion</jats:title><jats:p>By integrating curated strain-level pathogenicity annotations from BacSPaD with phylogeny-based OA, we introduce a novel approach and provide a novel resource for bacterial pathogenicity research.</jats:p></jats:sec>},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
Bonduelle, Olivia; Delory, Tristan; Moscardini, Isabelle Franco; Ghidi, Marion; Bennacer, Selma; Wokam, Michele; Lenormand, Mathieu; Petrier, Melissa; Rogeaux, Olivier; de Bernard, Simon; Alves, Karine; Nourikyan, Julien; Lina, Bruno; Combadiere, Behazine; Janssen, Cécile
Boosting effect of high-dose influenza vaccination on innate immunity among elderly: a randomized-control trial Article de journal
Dans: JCI Insight, 2025, ISSN: 2379-3708.
@article{pmid40036077,
title = {Boosting effect of high-dose influenza vaccination on innate immunity among elderly: a randomized-control trial},
author = {Olivia Bonduelle and Tristan Delory and Isabelle Franco Moscardini and Marion Ghidi and Selma Bennacer and Michele Wokam and Mathieu Lenormand and Melissa Petrier and Olivier Rogeaux and Simon de Bernard and Karine Alves and Julien Nourikyan and Bruno Lina and Behazine Combadiere and Cécile Janssen},
doi = {10.1172/jci.insight.184128},
issn = {2379-3708},
year = {2025},
date = {2025-03-01},
urldate = {2025-03-01},
journal = {JCI Insight},
abstract = {BACKGROUND: The high-dose quadrivalent influenza vaccine (QIV-HD) showed superior efficacy against laboratory-confirmed illness than the standard-dose quadrivalent influenza vaccine (QIV-SD) in randomized-controlled trials with elderly. However, specific underlying mechanism remains unclear.nnMETHODS: This Phase-IV randomized control trial compared early innate responses induced by QIV-HD and QIV-SD in 59 subjects aged >65 years. Systemic innate cells and gene signatures at Day (D) 0 and D1, hemagglutinin inhibition antibody (HIA) titers at D0 and D21 post-vaccination were assessed.nnRESULTS: QIV-HD elicited robust humoral response with significantly higher antibody titers and seroconversion rates than QIV-SD. At D1 post-vaccination, QIV-HD recipients showed significant reduction in innate cells, including conventional dendritic cells and natural killer cells than QIV-SD, correlating with significantly increased HIA titers at D21. Blood transcriptomic analysis revealed greater amplitude of gene expression in QIV-HD arm, encompassing genes related to innate immune response, interferons, and antigen processing and presentation and correlated with humoral responses. Interestingly, comparative analysis with a literature dataset from young adults vaccinated with influenza standard-dose vaccine highlighted strong similarities in gene expression patterns and biological pathways with the elderly vaccinated with QIV-HD.nnCONCLUSION: QIV-HD induces higher HIA titers than QIV-SD, a youthful boost of the innate gene expression significantly associated with high HIA titers.nnTRIAL REGISTRATION: EudraCT Number: 2021-004573-32.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}
2024
Ribeiro, Sara; Chaumet, Guillaume; Alves, Karine; Nourikyan, Julien; Shi, Lei; Lavergne, Jean-Pierre; Mijakovic, Ivan; de Bernard, Simon; Buffat, Laurent
BacSPaD: A Robust Bacterial Strains' Pathogenicity Resource Based on Integrated and Curated Genomic Metadata Article de journal
Dans: Pathogens, vol. 13, no. 8, 2024, ISSN: 2076-0817.
@article{pmid39204272,
title = {BacSPaD: A Robust Bacterial Strains' Pathogenicity Resource Based on Integrated and Curated Genomic Metadata},
author = {Sara Ribeiro and Guillaume Chaumet and Karine Alves and Julien Nourikyan and Lei Shi and Jean-Pierre Lavergne and Ivan Mijakovic and Simon de Bernard and Laurent Buffat},
doi = {10.3390/pathogens13080672},
issn = {2076-0817},
year = {2024},
date = {2024-08-01},
urldate = {2024-08-01},
journal = {Pathogens},
volume = {13},
number = {8},
abstract = {The vast array of omics data in microbiology presents significant opportunities for studying bacterial pathogenesis and creating computational tools for predicting pathogenic potential. However, the field lacks a comprehensive, curated resource that catalogs bacterial strains and their ability to cause human infections. Current methods for identifying pathogenicity determinants often introduce biases and miss critical aspects of bacterial pathogenesis. In response to this gap, we introduce BacSPaD (Bacterial Strains' Pathogenicity Database), a thoroughly curated database focusing on pathogenicity annotations for a wide range of high-quality, complete bacterial genomes. Our rule-based annotation workflow combines metadata from trusted sources with automated keyword matching, extensive manual curation, and detailed literature review. Our analysis classified 5502 genomes as pathogenic to humans (HP) and 490 as non-pathogenic to humans (NHP), encompassing 532 species, 193 genera, and 96 families. Statistical analysis demonstrated a significant but moderate correlation between virulence factors and HP classification, highlighting the complexity of bacterial pathogenicity and the need for ongoing research. This resource is poised to enhance our understanding of bacterial pathogenicity mechanisms and aid in the development of predictive models. To improve accessibility and provide key visualization statistics, we developed a user-friendly web interface.},
keywords = {},
pubstate = {published},
tppubtype = {article}
}